インサイダー取引

EDGAR

Immunome, Inc.

取締役、役員、10%超の株主がSECのForm 3、4、5で報告した取引を、各提出書類のXMLから読み取っています。コードとその文言はSEC自身のものです。

Form 4は取引から2営業日以内に提出する必要があるため、直近の取引はまだ提出されていない場合があります。

期間:2025年11月17日以降の日付の取引。

市場での購入(コードP)
11件の取引、111,468株
株数 × 1株あたり価格の合計:2,305,989.79
市場での売却(コードS)
28件の取引、1,228,648株
株数 × 1株あたり価格の合計:27,508,460.88

合計は掲載した提出済み取引を足したもので、報告された内容の集計であり、方向性を示すものではありません。

86件中1–50件を表示

SECのForm 3、4、5で提出されたインサイダー取引(新しい順)
日付報告者コード取得または処分株数1株あたり価格(提出どおり)価値(算出)取引後の保有株数直接または間接ルール10b5-1のチェック欄注記出典
2026年9月11日 2026年9月15日に提出Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)18,0001.35
24,300

算出:株数 × 1株あたり価格。正確な値 24300.00。

78,250直接(D) はい— 提出書類を開く 0001993684-26-000008 提出書類のXMLから読み取り この行に異議を申し立てる
2026年9月11日 2026年9月15日に提出Higgins Jack Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)13,20025.32
334,224

算出:株数 × 1株あたり価格。正確な値 334224.00。

65,050直接(D) はい
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
提出書類を開く 0001993684-26-000008 提出書類のXMLから読み取り この行に異議を申し立てる
2026年9月11日 2026年9月15日に提出Higgins Jack Officer: Chief Scientific Officer
G

Bona fide gift

Common Stock
処分(D)8,8000—56,250直接(D) はい— 提出書類を開く 0001993684-26-000008 提出書類のXMLから読み取り この行に異議を申し立てる
2026年9月11日 2026年9月15日に提出Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (18,000) — 行使価格 1.35
取得(A)18,0000—133,840直接(D) はい
F3
  • F3 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001993684-26-000008 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月12日 2026年8月12日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)11,04827.25
301,058

算出:株数 × 1株あたり価格。正確な値 301058.00。

92,211直接(D) はい
F5
  • F5 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
提出書類を開く 0001808343-26-000010 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月11日 2026年8月12日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)62,29126.23
1,633,892.93

算出:株数 × 1株あたり価格。正確な値 1633892.93。

0間接(I) See footnoteはい
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000010 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月10日 2026年8月12日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)10,12526.07
263,958.75

算出:株数 × 1株あたり価格。正確な値 263958.75。

62,291間接(I) See footnoteはい
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000010 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月7日 2026年8月10日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)15,24826.06
397,362.88

算出:株数 × 1株あたり価格。正確な値 397362.88。

72,416間接(I) See footnoteはい
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000009 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月6日 2026年8月10日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)20,84026.06
543,090.4

算出:株数 × 1株あたり価格。正確な値 543090.40。

87,664間接(I) See footnoteはい
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000009 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月4日 2026年8月6日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)50,36612.92
650,728.72

算出:株数 × 1株あたり価格。正確な値 650728.72。

50,366直接(D) はい— 提出書類を開く 0001831215-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月4日 2026年8月6日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)40,25010.60
426,650

算出:株数 × 1株あたり価格。正確な値 426650.00。

90,616直接(D) はい— 提出書類を開く 0001831215-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月4日 2026年8月6日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)90,61625.09
2,273,555.44

算出:株数 × 1株あたり価格。正確な値 2273555.44。

0直接(D) はい
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  • F2 The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001831215-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月4日 2026年8月6日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (50,366) — 行使価格 12.92
処分(D)50,3660—78,542直接(D) はい
F3
  • F3 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
提出書類を開く 0001831215-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年8月4日 2026年8月6日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (40,250) — 行使価格 10.60
処分(D)40,2500—120,750直接(D) はい
F4
  • F4 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
提出書類を開く 0001831215-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)38,2500—43,805直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001831144-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (76,500) — 行使価格 22.01
取得(A)76,5000—76,500直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001831144-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)38,2500—81,550直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0002026600-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (76,500) — 行使価格 22.01
取得(A)76,5000—76,500直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0002026600-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)31,2500—31,250直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001831215-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (62,500) — 行使価格 22.01
取得(A)62,5000—62,500直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001831215-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)47,2500—101,287直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001994071-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (94,500) — 行使価格 22.01
取得(A)94,5000—94,500直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001994071-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)54,0000—69,805直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001997584-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (108,000) — 行使価格 22.01
取得(A)108,0000—108,000直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001997584-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)180,0000—870,704直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001167496-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (360,000) — 行使価格 22.01
取得(A)360,0000—360,000直接(D) いいえ
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001167496-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)38,2500—60,250直接(D) いいえ
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001993684-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (76,500) — 行使価格 22.01
取得(A)76,5000—76,500直接(D) いいえ
F3
  • F3 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
提出書類を開く 0001993684-26-000006 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月7日 2026年7月9日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)1,09212.92
14,108.64

算出:株数 × 1株あたり価格。正確な値 14108.64。

1,092直接(D) はい— 提出書類を開く 0001831215-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月7日 2026年7月9日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)1,09225
27,300

算出:株数 × 1株あたり価格。正確な値 27300。

0直接(D) はい
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
提出書類を開く 0001831215-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月7日 2026年7月9日に提出Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (1,092) — 行使価格 12.92
処分(D)1,0920—128,908直接(D) はい
F2
  • F2 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
提出書類を開く 0001831215-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月7日 2026年7月7日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)16,90624.20
409,125.2

算出:株数 × 1株あたり価格。正確な値 409125.20。

108,504間接(I) See footnoteはい
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月6日 2026年7月7日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)83,09424.11
2,003,396.34

算出:株数 × 1株あたり価格。正確な値 2003396.34。

125,410間接(I) See footnoteはい
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月7日に提出Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)55,0008.73
480,150

算出:株数 × 1株あたり価格。正確な値 480150.00。

70,805直接(D) はい— 提出書類を開く 0001997584-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月7日に提出Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)22,71421.95
498,572.3

算出:株数 × 1株あたり価格。正確な値 498572.30。

48,091直接(D) はい
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001997584-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月7日に提出Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)16,21422.76
369,030.64

算出:株数 × 1株あたり価格。正確な値 369030.64。

31,877直接(D) はい
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001997584-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月7日に提出Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)16,07223.44
376,727.68

算出:株数 × 1株あたり価格。正確な値 376727.68。

15,805直接(D) はい
F1, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F4 The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001997584-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月7日に提出Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (55,000) — 行使価格 8.73
処分(D)55,0000—290,000直接(D) はい
F5
  • F5 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
提出書類を開く 0001997584-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月2日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)75,66522.35
1,691,112.75

算出:株数 × 1株あたり価格。正確な値 1691112.75。

232,839間接(I) See footnoteはい
F1, F6, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F6 The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月2日 2026年7月2日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)24,33523.33
567,735.55

算出:株数 × 1株あたり価格。正確な値 567735.55。

208,504間接(I) See footnoteはい
F1, F8, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F8 The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月30日 2026年7月2日に提出Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)101,05021.12
2,134,176

算出:株数 × 1株あたり価格。正確な値 2134176.00。

308,504間接(I) See footnotesはい
F1, F2, F3, F4, F5
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F2 The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.
  • F3 The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F4 The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC (ABV II) and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.
  • F5 The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
提出書類を開く 0001808343-26-000005 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月25日 2026年6月29日に提出Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)55,0008.73
480,150

算出:株数 × 1株あたり価格。正確な値 480150.00。

70,805直接(D) はい— 提出書類を開く 0001997584-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月25日 2026年6月29日に提出Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)40,58019.56
793,744.8

算出:株数 × 1株あたり価格。正確な値 793744.80。

30,225直接(D) はい
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001997584-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月25日 2026年6月29日に提出Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)14,42020.66
297,917.2

算出:株数 × 1株あたり価格。正確な値 297917.20。

15,805直接(D) はい
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
提出書類を開く 0001997584-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月25日 2026年6月29日に提出Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Employee Stock Option (right to buy) — 原資産 Common Stock (55,000) — 行使価格 8.73
処分(D)55,0000—345,000直接(D) はい
F4
  • F4 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
提出書類を開く 0001997584-26-000002 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月15日 2026年6月17日に提出Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)60,0001.05
63,000

算出:株数 × 1株あたり価格。正確な値 63000.00。

114,037直接(D) はい— 提出書類を開く 0001994071-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月15日 2026年6月17日に提出Rosett Max Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
処分(D)60,00018.23
1,093,800

算出:株数 × 1株あたり価格。正確な値 1093800.00。

54,037直接(D) はい
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
  • F2 The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
提出書類を開く 0001994071-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月15日 2026年6月17日に提出Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

デリバティブ証券: Stock Option (right to buy) — 原資産 Common Stock (60,000) — 行使価格 1.05
処分(D)60,0000—0直接(D) はい
F3
  • F3 The option is fully vested.
提出書類を開く 0001994071-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月10日 2026年6月12日に提出WAGENHEIM PHILIP Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Director Stock Option (right to buy) — 原資産 Common Stock (9,897) — 行使価格 18.16
取得(A)9,8970—9,897直接(D) いいえ
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
提出書類を開く 0001405684-26-000003 提出書類のXMLから読み取り この行に異議を申し立てる
2026年6月10日 2026年6月12日に提出BIENAIME JEAN JACQUES Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Director Stock Option (right to buy) — 原資産 Common Stock (9,897) — 行使価格 18.16
取得(A)9,8970—9,897直接(D) いいえ
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
提出書類を開く 0001221590-26-000018 提出書類のXMLから読み取り この行に異議を申し立てる

機関投資家の保有(Form 13F)

この発行体に結び付いたForm 13Fの保有はストアにありません。未リンクまたは未提出の保有者はゼロではなく、不在です。

5%保有者(Schedule 13D・13G)

SECの構造化形式(2024年末以降)で提出されたスケジュールをここで読み取ります。それ以前のものは自由形式のテキストで、読み取っていません。

5%保有者(新しい事由順、提出どおり)
保有者クラスに占める割合保有株数事由日書式出典
Vanguard Capital Management Common Stock5.045,725,57809/30/2026 2026年10月30日に提出SCHEDULE 13G提出書類を開く 0002100119-26-001633 この行に異議を申し立てる
T. Rowe Price Investment Management, Inc. COMMON STOCK17.419,676,88306/30/2026 2026年8月14日に提出SCHEDULE 13G/A訂正 2提出書類を開く 0001897612-26-000609 この行に異議を申し立てる
Sirenia Capital Management LP Common Stock, par value $0.0001 per share4.34,832,279.0006/30/2026 2026年8月14日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000919574-26-005205 この行に異議を申し立てる
Alex Silverstein Common Stock, par value $0.0001 per share4.34,832,279.0006/30/2026 2026年8月14日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000919574-26-005205 この行に異議を申し立てる
Sirenia Capital Management LP Common Stock, par value $0.0001 per share6.16,895,000.0003/31/2026 2026年5月15日に提出SCHEDULE 13G提出書類を開く 0000919574-26-003222 この行に異議を申し立てる
Alex Silverstein Common Stock, par value $0.0001 per share6.16,895,000.0003/31/2026 2026年5月15日に提出SCHEDULE 13G提出書類を開く 0000919574-26-003222 この行に異議を申し立てる
T. Rowe Price Investment Management, Inc. COMMON STOCK14.516,364,01103/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0001897612-26-000495 この行に異議を申し立てる
Redmile Group, LLC Common Stock, $0.0001 par value per share4.95,558,885.0003/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 4提出書類を開く 0001104659-26-062570 この行に異議を申し立てる
Jeremy C. Green Common Stock, $0.0001 par value per share4.95,558,885.0003/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 4提出書類を開く 0001104659-26-062570 この行に異議を申し立てる
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share00.0003/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000919574-26-003480 この行に異議を申し立てる
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share00.0003/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000919574-26-003480 この行に異議を申し立てる
Steven A. Cohen Common Stock, par value $0.0001 per share00.0003/31/2026 2026年5月15日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000919574-26-003480 この行に異議を申し立てる
The Vanguard Group Common Stock0003/13/2026 2026年3月26日に提出SCHEDULE 13G/A訂正 3提出書類を開く 0000102909-26-000422 この行に異議を申し立てる
Redmile Group, LLC Common Stock, $0.0001 par value per share5.25,718,385.0012/31/2025 2026年2月17日に提出SCHEDULE 13G/A訂正 3提出書類を開く 0001104659-26-016437 この行に異議を申し立てる
Jeremy C. Green Common Stock, $0.0001 par value per share5.25,718,385.0012/31/2025 2026年2月17日に提出SCHEDULE 13G/A訂正 3提出書類を開く 0001104659-26-016437 この行に異議を申し立てる
Enavate Sciences GP, LLC Common Stock, par value $0.0001 per share4.34,768,583.0012/18/2025 2025年12月22日に提出SCHEDULE 13D/A訂正 2提出書類を開く 0001953107-25-000019 この行に異議を申し立てる
Immunome Aggregator, LP Common Stock, par value $0.0001 per share4.34,768,583.0012/18/2025 2025年12月22日に提出SCHEDULE 13D/A訂正 2提出書類を開く 0001953107-25-000019 この行に異議を申し立てる
T. Rowe Price Investment Management, Inc. COMMON STOCK12.210,644,67410/31/2025 2025年11月7日に提出SCHEDULE 13G提出書類を開く 0001897612-25-000510 この行に異議を申し立てる
FMR LLC COMMON STOCK15.013,056,709.1109/30/2025 2025年10月7日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000315066-25-002307 この行に異議を申し立てる
Abigail P. Johnson COMMON STOCK15.013,056,709.1109/30/2025 2025年10月7日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000315066-25-002307 この行に異議を申し立てる
FMR LLC COMMON STOCK7.16,167,666.0006/30/2025 2025年8月6日に提出SCHEDULE 13G提出書類を開く 0000315066-25-002061 この行に異議を申し立てる
Abigail P. Johnson COMMON STOCK7.16,167,666.0006/30/2025 2025年8月6日に提出SCHEDULE 13G提出書類を開く 0000315066-25-002061 この行に異議を申し立てる
The Vanguard Group Common Stock5.204,524,95206/30/2025 2025年7月29日に提出SCHEDULE 13G提出書類を開く 0000932471-25-000844 この行に異議を申し立てる

割合は提出書類が指定するクラスに対するもので、保有者の申告どおりです。グループの構成員はそれぞれグループの株式を報告するため、行を合算しないでください。

読み込んだ内容

2004年6月14日から2026年11月13日までの提出書類2,116,845件を読み込み:Form 3, 3/A, 4, 4/A, 5, 5/A。

アーカイブの読み込み中は、不完全な年があります。ここで提出数が少ない年が、実際に少なかったという意味ではありません。

提出年別の読み込み件数
提出年読み込み件数
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024209,823
2025235,520
2026254,737

SECがXMLを義務付ける前の提出書類は一覧にあるだけで、内容は抽出していません。

Immunome, Inc.に戻る